Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeQUREuniQure$28.10+16.3%$16.67$8.73▼$71.50$1.74B0.872.81 million shs1.45 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceQUREuniQure+5.83%+21.05%+40.90%-5.85%+139.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeQUREuniQure$28.10+16.3%$16.67$8.73▼$71.50$1.74B0.872.81 million shs1.45 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceQUREuniQure+5.83%+21.05%+40.90%-5.85%+139.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceQUREuniQure 2.53Moderate Buy$42.8352.45% UpsideCurrent Analyst Ratings BreakdownLatest QURE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $50.005/5/2026QUREuniQure Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$28.004/30/2026QUREuniQure Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $37.004/20/2026QUREuniQure The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$9.00 ➝ $10.003/23/2026QUREuniQure BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$31.00 ➝ $25.003/11/2026QUREuniQure MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$12.00 ➝ $35.003/10/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.003/9/2026QUREuniQure Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$16.00 ➝ $31.003/9/2026QUREuniQure Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSector Perform ➝ Outperform$11.00 ➝ $35.003/9/2026QUREuniQure Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$15.00 ➝ $60.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookQUREuniQure$18.09M97.93N/AN/A$2.37 per share11.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateQUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%N/ALatest QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 million3/3/2026Q4 2025QUREuniQure-$0.93-$0.56+$0.37-$0.56$4.84 million$5.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioQUREuniQure0.3310.4010.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipQUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipQUREuniQure4.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableQUREuniQure50063.07 million60.05 millionOptionableQURE HeadlinesRecent News About These CompaniesHC Wainwright Issues Optimistic Outlook for uniQure EarningsMay 8 at 7:36 AM | marketbeat.comFDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?May 7 at 8:43 PM | fiercepharma.comFWhat is HC Wainwright's Forecast for uniQure Q1 Earnings?May 7 at 8:16 AM | marketbeat.comUniQure plans UK AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029May 7 at 3:03 AM | msn.comUniQure plans U.K. AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029May 5 at 8:58 PM | seekingalpha.comuniQure Q1 Earnings Call HighlightsMay 5 at 4:19 PM | marketbeat.comuniQure N.V. (QURE) Q1 2026 Earnings Call TranscriptMay 5 at 4:04 PM | seekingalpha.comuniQure (NASDAQ:QURE) Issues Quarterly Earnings ResultsMay 5 at 11:29 AM | marketbeat.comuniQure (QURE) Reports Q1 Loss, Misses Revenue EstimatesMay 5 at 9:26 AM | zacks.comUniQure: Q1 Earnings SnapshotMay 5 at 9:20 AM | chron.comuniQure Announces First Quarter 2026 Financial Results and Provides Recent Company UpdatesMay 5 at 7:05 AM | globenewswire.comHow The uniQure (QURE) Investment Story Is Shifting With AMT-130 And Regulatory UncertaintyMay 4, 2026 | finance.yahoo.comuniQure (NASDAQ:QURE) Shares Up 6.3% - Still a Buy?May 4, 2026 | marketbeat.comuniQure N.V. (NASDAQ:QURE) Receives $42.83 Consensus Price Target from AnalystsMay 4, 2026 | americanbankingnews.comuniQure’s AMT-130 Regulatory Progress Sharpens Huntington’s Disease Investment CaseMay 3, 2026 | finance.yahoo.comJennison Associates LLC Boosts Stake in uniQure N.V. $QUREMay 2, 2026 | marketbeat.comuniQure (QURE) Expected to Announce Quarterly Earnings on TuesdayMay 1, 2026 | americanbankingnews.comuniQure (QURE) Projected to Post Earnings on TuesdayMay 1, 2026 | marketbeat.comUniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrelApril 30, 2026 | biospace.comBuniQure meets with UK MHRA on AMT-130 for Huntington’s diseaseApril 30, 2026 | thepharmaletter.comTUniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapyApril 30, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQURE Company DescriptionsuniQure NASDAQ:QURE$28.10 +3.95 (+16.34%) As of 01:29 PM Eastern This is a fair market value price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
